AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00362219
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel with 0.75 mg morphine per 100cm2 square of wound.
Trial: NCT00362219
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel with 1.25 mg morphine per 100cm2 square of wound.
Trial: NCT06490536
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Trial: NCT06490536
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Trial: NCT06490536
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Trial: NCT06490536
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Trial: NCT06490536
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Trial: NCT06530251
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a predefined dose and date.
Trial: NCT06530251
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a predefined dose and date.
Trial: NCT06530251
Drug: AK127
RxNorm normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Following a predefined dose and date.
Trial: NCT05300672
Drug: fibrinogen infusion
RxNorm normalized name: fibrinogen
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
Trial: NCT06530251
Drug: AK130
RxNorm normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following a predefined dose and date.
Trial: NCT06530251
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the local label direction.
Trial: NCT06530251
Drug: Bevacizumab biosimilar
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following the local label direction.
Trial: NCT06487000
Drug: EC-18
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, QD
Trial: NCT05469165
Drug: Cyproheptadine 4 Mg Oral Tablet
RxNorm normalized name: cyproheptadine 4 mg oral tablet
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine treatment for 3 months
Trial: NCT06414395
Drug: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
RxNorm normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
Trial: NCT01130259
Drug: iniparib
RxNorm normalized name: Iniparib
DrugBank: Iniparib (DB13877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
Trial: NCT06205836
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Trial: NCT06205836
Drug: Fianlimab
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Trial: NCT06323369
Drug: Tislelizumab（neoadjuvant）
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT04836962
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
Trial: NCT06323369
Drug: Cisplatin （neoadjuvant）
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06323369
Drug: Nab-paclitaxel （neoadjuvant）
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06323369
Drug: Cisplatin（adjuvant）
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06323369
Drug: Tislelizumab（adjuvant）
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06323369
Drug: Carboplatin（neoadjuvant）
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06323369
Drug: Carboplatin（adjuvant）
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT05785325
Drug: RC48-ADC plus Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
Trial: NCT05127525
Drug: IRX-101
RxNorm normalized name: IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Trial: NCT05127525
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Trial: NCT06273943
Drug: Cabotegravir Tablets, for oral use.
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
Trial: NCT04689932
Drug: Triferic AVNU
RxNorm normalized name: FERRIC PYROPHOSPHATE CITRATE 1.5 mg in 1 mL INTRAVENOUS SOLUTION [Triferic AVNU]
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric Pyrophosphate Citrate
Trial: NCT06273943
Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
Trial: NCT04971200
Drug: Tildrakizumab
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 100mg subcutaneous injections Q4W
Trial: NCT05305885
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
Trial: NCT06273943
Drug: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient.
Trial: NCT06510582
Drug: Bevacizumab 2 mg/kg
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
Trial: NCT06510582
Drug: Bevacizumab 4 mg/kg
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
Trial: NCT06141330
Drug: Adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retinoid
Trial: NCT05867654
Drug: Amoxicillin-clavulanate 875mg/125mg q12hrs
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral antibiotic used based on indication
Trial: NCT05867654
Drug: Levofloxacin 750mg QID
RxNorm normalized name: levofloxacin 750 MG
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral antibiotic used based on indication
Trial: NCT05127876
Drug: Ondansetron 4 MG
RxNorm normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
Trial: NCT05127876
Drug: Ondansetron 8mg
RxNorm normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
Trial: NCT05127876
Drug: EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution
RxNorm normalized name: ePHEDrine 10 mg/mL-NaCl 0.9% intravenous solution
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
Trial: NCT05018923
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg bid
Trial: NCT05018923
Drug: Bismuth potassium citrate
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6g bid
Trial: NCT05018923
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4g qid
Trial: NCT05620498
Drug: tislelizumab+lenvatinib+GMOX
RxNorm normalized name: Tislelizumab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
Trial: NCT05620498
Drug: tislelizumab+GEMOX
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab+GEMOX
Trial: NCT06664996
Drug: Sintilimab (approved)
RxNorm normalized name: glucose
DrugBank: Sintilimab (DB15765)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).
Trial: NCT06173037
Drug: RC88
RxNorm normalized name: RC88
DrugBank: RC88 (DB18697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg Q3W IV
Trial: NCT05650645
Drug: incobotulinum toxin A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
Trial: NCT05417880
Drug: Voreta plus SunnyD PRO
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Pro Vent Plus]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
Trial: NCT06574945
Drug: intravenous injection of propofol only
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol was administered intravenously 2 mg/kg
Trial: NCT06574945
Drug: intravenous injection of propofol +esketamine
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol
Trial: NCT05085626
Drug: fluzoparib+chidamide
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms A will be treated with fluzoparib in combination with cedaramide
Trial: NCT05085626
Drug: fluzoparib+camrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arms B will be treated with fluzoparib in combination with camrelizumab
Trial: NCT06666673
Drug: Tizanidine
RxNorm normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.
Trial: NCT04954599
Drug: CP-506
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
Trial: NCT04954599
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antineoplastic agent, ATC Code: LO1X A02
Trial: NCT04954599
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
Trial: NCT05123079
Drug: Darigabat
RxNorm normalized name: Darigabat
DrugBank: Darigabat (DB18966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT06256289
Drug: Canagliflozin 100mg Tab
RxNorm normalized name: CANAGLIFLOZIN 100MG TAB
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
Trial: NCT06256289
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1000mg twice daily
Trial: NCT05765279
Drug: HH-120 nasal spray 1
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH-120 nasal spray 5 times daily for 3 consecutive days
Trial: NCT05765279
Drug: HH-120 nasal spray 2
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH-120 nasal spray 8 times daily for 3 consecutive days
Trial: NCT06418724
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR). EGFR is over-expressed in many human cancers, including colorectal cancers.
Trial: NCT06418724
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
Trial: NCT05234736
Drug: CBL-514
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)
Trial: NCT05204862
Drug: Anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered
Trial: NCT06684249
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.
Trial: NCT05505877
Drug: BR790+Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose.
Trial: NCT05087381
Drug: FluvoxaMINE Maleate 50 MG
RxNorm normalized name: fluvoxamine maleate 50 MG
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Trial: NCT06444256
Drug: SUVO
RxNorm normalized name: Rasuvo
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
Trial: NCT06444256
Drug: TAU
RxNorm normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.